Regeneron announces upcoming presentations at Angiogenesis annual meeting

Regeneron (REGN) Pharmaceuticals announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis annual meeting on February 7, 2026. These include new clinical data supporting the efficacy and safety of EYLEA HD Injection 8 mg for treating patients with serious retinal diseases. “New presentations will further highlight the EYLEA HD clinical profile, showcasing its unparalleled durability, while allowing similar efficacy and safety to EYLEA 2 mg, but with fewer injections. This includes the Phase 3 data supporting EYLEA HD approval in RVO, where its durability offers the first every-two-month treatment option in the setting, prior to which monthly treatment was required with all other anti-VEGF agents,” said Boaz Hirshberg, M.D., Senior Vice President, Clinical Development, Internal Medicine at Regeneron. “In addition, while EYLEA HD allows for most patients to achieve longer dosing intervals, data will also be presented from the ELARA trial, supporting EYLEA HD approval as a monthly treatment for the small number of patients who need more frequent treatment. Presentations will show that patients who switched to monthly EYLEA HD from other anti-VEGF agents generally improved their vision, while also achieving better anatomic control.”